Home Stocks Wockhardt Ltd

Wockhardt Ltd

The live share price of Wockhardt Ltd (WOCKPHARMA) as on 04 Oct 10:17am is ₹229.6 from NSE/BSE.

WOCKPHARMA NSE

₹229.6 ▼-3.24% (-7.7)

As on Oct 04, 2023 03:47 PM IST

How do you feel today about Wockhardt Ltd?

Bearish or

Bullish

Bearish or

Bullish

Key Metrics

PE Ratio

-5.41

PB Ratio

0.93

Dividend Yield

-

Sector PB

4.77

Sector PE

40.65

Sector Div Yld

0.76%

Dividend Yield

Dividend per share for the most recent financial year divided by the close price

About

Sector

Health Care

Industry

Pharmaceuticals

Market Cap

Smallcap, ₹3,389 Cr

Wockhardt Limited manufactures and markets pharmaceutical and bio-pharmaceutical formulations, active pharmaceutical ingredients (APIs) and vaccines.

The following charts display the financial performance of the Wockhardt Ltd (WOCKPHARMA) stock, including the year-on-year Income Statement , Balance Sheet , Cash Flow Statement and Shareholding pattern.

Furthermore, under the Peers section, you can find stocks that are similar to Wockhardt Ltd (WOCKPHARMA), and their live stock price and performance at a glance. Click on any peer stock to navigate to that stock’s live price page.

✅ If you’re new to investing in the stock market, and/or are unsure about your investment options, you can explore smallcases.

A smallcase is a readymade stock/ETF portfolio (also known as a stock basket) that is based on an investment idea, theme or strategy. Examples of popular smallcases include All Weather Investing , Equity and Gold , Top 100 Stocks , Green Energy and Value & Momentum.

All smallcases are created and managed by SEBI-registered investment experts.

To invest in smallcases, all you need is a demat/trading account. You retain complete ownership of the smallcase’s constituent stocks or ETFs, as they are directly credited to your broking account. You can choose from over 500+ smallcases across 180+ smallcase managers to start your investment journey.

Sector

Health Care

Industry

Pharmaceuticals

Market Cap

Smallcap, ₹3,389 Cr

Financials

Income Statement

(INR)		Y/Y Change
Revenue	2,773 Cr	-14.68%
Operating Expense	751 Cr	+9.8%
Net Income	-559 Cr	+129.1%
Net Profit Margin	-20.16%	+168.44%
Earning Per Share	-38	+110.12%
EBITDA	-71 Cr	-152.59%

Balance sheet

(INR)		Y/Y Change
Cash & short-term Inv	124 Cr	-69.46%
Total Assets	7,651 Cr	-6.87%
Total Liabilities	3,989 Cr	-0.6%
Total Equity	3,662 Cr	-12.85%
Shares Outstanding	14.41 Cr	+0.03%
Price to Book	0.61	-37.09%
Return on Assets	-7.05%	+130.39%
Return on Capital	-8.79 Cr	+229.21%

Cash Flows

(INR)		Y/Y Change
Net Income	-559 Cr	+129.1%
Cash from Operations	153 Cr	-62.95%
Cash from Investing	-118 Cr	-42.16%
Cash from Financing	-315 Cr	+343.66%
Net Change in Cash	-280 Cr	-302.9%
Free Cash Flow	-56 Cr	-127.86%

Shareholding Pattern

Total Promoter Holding

58.4%

Unpledged

Foreign Institutions

2.59%

Foreign Institutions

Retail & Others

38.81%

Retail & Others

Other Parties

Other Domestic Institutions

0.19%

Insurance Firms

Others

Mutual Funds

0%

Mutual Funds

Peers

SUNPHARMA

Sun Pharmaceutical Industries Ltd

PE Ratio

32.96

1Y Return

▲20.85%

CIPLA

Cipla Ltd

PE Ratio

30.78

1Y Return

▲4.6%

DRREDDY

Dr Reddy's Laboratories Ltd

PE Ratio

19.69

1Y Return

▲23.58%

MANKIND

Mankind Pharma Ltd

PE Ratio

48.72

1Y Return

▲26.44%

Latest News

Wockhardt shareholders reject proposal to raise Rs 1,600 crore from promotor

1 month ago on Economic Times

Change since news ▲0.65%

IiAS said the proposed related party transaction with KHIPL was intended for borrowing of funds for an amount up to Rs 1,600 crore for a period of two years renewable by mutual consent, subject to ratification by members at least once in every five years, IiAS said.

Stocks that will see action today: August 17, 2023

2 months ago on The Hindu Businessline

Change since news ▲0.97%

Lupin launches generic COPD treatment in US; Criisl upgrades Aditya Vision’s rating; Aurobindo gets USFDA nod for HIV drug; Govt to sell part of IRFC stake; Antfin transfers 10.3% stake in One97 to Sharma; PFC gets first full-time women CMD; Nava Ltd suffers accidental damage; Wockhardt shareholder…

Wockhardt Consolidated June 2023 Net Sales at Rs 644.00 crore, up 8.24% Y-o-Y

2 months ago on Moneycontrol

Change since news ▲9.52%

NULL

FAQs on Wockhardt Ltd

How to buy Wockhardt Ltd stocks?

You can easily buy the stocks/shares of Wockhardt Ltd (WOCKPHARMA) through either a broker or a financial institution by opening a Demat & Trading account online via smallcase.

What is the Share Price of Wockhardt Ltd?

The stock price of Wockhardt Ltd as on 04 Oct 2023 is ₹229.6

What is the 52-week High and Low of Wockhardt Ltd?

The 52-week high and low of Wockhardt Ltd (WOCKPHARMA) is ₹269.1 and ₹145.15.

What is the PE and PB ratio of Wockhardt Ltd?

The P/E (price-to-earnings) and P/B (price-to-book) ratios of Wockhardt Ltd are -5.41 and 0.93 respectively.

What are the peers or stocks similar to Wockhardt Ltd?

The peers or stocks similar to Wockhardt Ltd are Sun Pharmaceutical Industries Ltd, Cipla Ltd, Dr Reddy's Laboratories Ltd, Mankind Pharma Ltd and many others. smallcase also offers over 200 readymade stock baskets managed by 180+ SEBI-registered investment experts. These stock portfolios are based on a theme, idea or strategy. You can use smallcase to start investing in diversified stock baskets.

Which sector does Wockhardt Ltd belong to?

Wockhardt Ltd (WOCKPHARMA) belongs to the Pharmaceuticals sector.

What is the Market Cap of Wockhardt Ltd?

Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Wockhardt Ltd (WOCKPHARMA) is ₹3,389 Cr as of 04 Oct 2023

Can't decide whether or not to buy Wockhardt Ltd stocks? ⭐️

Worry no more! smallcase offers readymade stock baskets/portfolios that are based on an theme, idea or strategy. You can choose from more than 500+ stock portfolios managed by 180+ SEBI-registered investment experts.

Dislaimer: This platform is intended for informational purposes only and is not intended to provide investment advice. The stock prices displayed are delayed and may not reflect the most current market conditions. Investment in securities market are subject to market risks. Read all the related documents carefully before investing. You can also consider consulting a financial advisor before making any investment decisions. Smallcase Technologies Private Limited shall not be responsible for any losses that may occur as a result of using this platform.